Mumbai, Naples, July 4, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent® Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals, Inc.

Ipratropium Bromide Nasal Solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older.  Ipratropium Bromide Nasal Solution (Nasal Spray) 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older.

Ipratropium Bromide Nasal Solution (RLD Atrovent®) had estimated annual sales of USD 63 million in the U.S. (IQVIA MAT May 2025).

 About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com  or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries please contact –
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com

*Safe Harbor Statement
Atrovent® is a registered trademark of Boehringer Ingelheim International GmbH